Royal Philips, a renowned player in health technology, has unveiled its advanced AI-powered cardiovascular ultrasound platform, which seamlessly integrates into the EPIQ CVx and Affiniti CVx systems. These new FDA-cleared AI applications automate measurements and streamline workflows, boosting productivity in echocardiography labs. Heart failure, affecting approximately 64 million people worldwide, significantly burdens healthcare systems. Cardiovascular ultrasound, the most common non-invasive method for examining heart structure and function, plays a crucial role in early cardiac disease diagnosis. The AI integration allows for faster, more accurate analysis and improves diagnostic capabilities and patient care.
Dr. Roberto Lang from the University of Chicago Medicine emphasized that AI automates complex steps in echocardiography, enhancing clinicians' decision-making and efficiency. Philips' AI tools, developed with partners like NVIDIA, accurately detect regional wall motion abnormalities, a key indicator of cardiovascular events. These innovations, trained on anonymized patient data, ensure consistent image interpretation, reducing re-scans and shortening intervention times. Philips also introduced the X11 4t mini ultrasound transducer, to enhance care for a broader patient range, including pediatric cases. Through ongoing innovation and collaborations, Philips aims to improve cardiology care quality and efficiency amid increasing patient volumes and staff shortages.
